Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection
Mondal, Shakhinur Islam
Draper, Lorraine A.
Ross, R. Paul
Taylor & Francis Group
Clostridioides difficile is the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment of C. difficile infections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages of C. difficile and their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues of C. difficile endolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.
Clostridioides difficile , Endolysin , Bacteriophage , Antimicrobials , Clostridioides difficile infections , Antibiotics , Novel therapy
Mondal, S. I., Draper, L. A., Ross, R. P. and Hill, C. (2020) 'Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection', Gut Microbes, 12(1), e1813533 (15pp). doi: 10.1080/19490976.2020.1813533
© 2020, the Authors. Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.